

By: Representative Arnold

To: Drug Policy

HOUSE BILL NO. 663

1 AN ACT TO AMEND SECTION 41-29-113, MISSISSIPPI CODE OF 1972,  
2 TO ADD KRATOM TO SCHEDULE I OF THE UNIFORM CONTROLLED SUBSTANCES  
3 ACT; AND FOR RELATED PURPOSES.

4 BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF MISSISSIPPI:

5 **SECTION 1.** Section 41-29-113, Mississippi Code of 1972, is  
6 amended as follows:

7 41-29-113.

8 **SCHEDULE I**

9 (a) Schedule I consists of the drugs and other substances,  
10 by whatever official name, common or usual name, chemical name, or  
11 brand name designated, that is listed in this section.

12 (b) **Opiates.** Unless specifically excepted or unless listed  
13 in another schedule, any of the following opiates, including their  
14 isomers, esters, ethers, salts and salts of isomers, esters and  
15 ethers, whenever the existence of these isomers, esters, ethers  
16 and salts is possible within the specific chemical designation:

17 (1) Acetyl-alpha-methylfentanyl;



- 18                   (2)   Acetyl Fentanyl  
19 N-(1-phenethylpiperidin-4-yl)-N-phenylacetamide;  
20                   (3)   AH-7921 (3,4-dichloro-N-[(1-dimethylamino)  
21 cyclohexylmethyl]benzamide);  
22                   (4)   Acetylmethadol;  
23                   (5)   Allylprodine;  
24                   (6)   Alphacetylmethadol, except levo-alphacetylmethadol  
25 (levo-alpha-acetylmethadol, levomethadyl acetate, or LAAM);  
26                   (7)   Alphameprodine;  
27                   (8)   Alphamethadol;  
28                   (9)   Alpha-methylfentanyl;  
29                   (10)  Alpha-methylthiofentanyl;  
30                   (11)  Benzethidine;  
31                   (12)  Betacetylmethadol;  
32                   (13)  Beta-hydroxyfentanyl;  
33                   (14)  Beta-hydroxy-3-methylfentanyl;  
34                   (15)  Betameprodine;  
35                   (16)  Betamethadol;  
36                   (17)  Betaprodine;  
37                   (18)  Butyrl fentanyl  
38 (N-(1-phenethylpiperidin-4-yl)-N-phenylbutyramide);  
39                   (19)  Clonitazene;  
40                   (20)  Dextromoramide;  
41                   (21)  Diampromide;  
42                   (22)  Diethylthiambutene;



- 43                   (23)   Difenoxin;
- 44                   (24)   Dimenoxadol;
- 45                   (25)   Dimepheptanol;
- 46                   (26)   Dimethylthiambutene;
- 47                   (27)   Dioxaphetyl butyrate;
- 48                   (28)   Dipipanone;
- 49                   (29)   Ethylmethylthiambutene;
- 50                   (30)   Etonitazene;
- 51                   (31)   Etoxeridine;
- 52                   (32)   Fentanyl-related substances, meaning any substance
- 53 not otherwise listed under another schedule and for which no
- 54 exemption or approval is in effect under Section 505 of the
- 55 Federal Food, Drug, and Cosmetic Act [21 USC 355] that is
- 56 structurally related to fentanyl by one or more of the following
- 57 modifications:
- 58                   (A)   Replacement of the phenyl portion of the
- 59 phenethyl group by any monocycle, whether or not further
- 60 substituted in or on the monocycle;
- 61                   (B)   Substitution in or on the phenethyl group with
- 62 alkyl, alkenyl, alkoxy, hydroxyl, halo, haloalkyl, amino or nitro
- 63 groups;
- 64                   (C)   Substitution in or on the piperidine ring with
- 65 alkyl, alkenyl, alkoxy, ester, ether, hydroxyl, halo, haloalkyl,
- 66 amino or nitro groups;



67 (D) Replacement of the aniline ring with any  
68 aromatic monocycle whether or not further substituted in or on the  
69 aromatic monocycle; and/or

70 (E) Replacement of the N-propionyl group by  
71 another acyl group.

72 Fentanyl-related substances include, but are not limited to,  
73 cyclopropyl fentanyl,

74 (N-(1-phenethylpiperidin-4-yl)-N-phenylcyclopropanecarboxamide);

75 Furanyl-Fentanyl,

76 (N-(1-phenethylpiperidin-4-yl)-N-phenylfuran-2-carboxamide);

77 valeryl fentanyl,

78 (N-(1-phenethylpiperidin-4-yl)-N-phenylpentanamide);

79 para-fluorobutyryl fentanyl,

80 (N-(4-fluorophenyl)-N-(1-phenethylpiperidin-4-yl)butyramide);

81 para-methoxybutyryl fentanyl,

82 (N-(4-methoxyphenyl)-N-(1-phenethylpiperidin-4-yl)butyramide);

83 para-chloroisobutyryl fentanyl,

84 (N-(4-chlorophenyl)-N-(1-phenethylpiperidin-4-yl)isobutyramide);

85 isobutyryl fentanyl,

86 (N-(1-phenethylpiperidin-4-yl)-N-phenylisobutyramide);

87 cyclopentyl fentanyl,

88 (N-(1-phenethylpiperidin-4-yl)-N-phenylcyclopentanecarboxamide);

89 and



90 ocfentanil,  
91 (N-(2-fluorophenyl)-2-methoxy-N-(1-phenethylpiperidin-4-yl)acetami  
92 de);  
93 (33) Furethidine;  
94 (34) Hydroxypethidine;  
95 (35) Isotonitazene (N,N-diethyl-2-(2-(4  
96 isopropoxybenzyl)-5-nitro-1H-benzimidazol-1-yl)ethan-1-amine);  
97 (36) Ketobemidone (including the optical and geometric  
98 isomers);  
99 (37) Levomoramide;  
100 (38) Levophenacylmorphan;  
101 (39) 3-methylfentanyl;  
102 (40) 3-methylthiofentanyl;  
103 (41) Morpheridine;  
104 (42) MPPP (1-methyl-4-phenyl-4-propionoxypiperidine);  
105 (43)  
106 *N*-[1-[2-hydroxy-2-(thiophen-2-yl)ethyl]piperidin-4-yl]-*N*-phenylprop  
107 ionamide, its isomers, esters, ethers, salts and salts of isomers,  
108 esters and ethers (other names: beta-hydroxythiofentanyl);  
109 (44) Noracymethadol;  
110 (45) Norlevorphanol;  
111 (46) Normethadone;  
112 (47) Norpipanone;  
113 (48) Para-fluorofentanyl;



114 (49) PEPAP  
115 (1-(-2-phenethyl)-4-phenyl-4-acetoxypiperidine);  
116 (50) Phenadoxone;  
117 (51) Phenampromide;  
118 (52) Phenomorphan;  
119 (53) Phenoperidine;  
120 (54) Piritramide;  
121 (55) Proheptazine;  
122 (56) Properidine;  
123 (57) Propiram;  
124 (58) Racemoramide;  
125 (59) Thiofentanyl;  
126 (60) Tilidine;  
127 (61) Trimeperidine;  
128 (62) U-47700,  
129 3,4-dichloro-N-[2-(dimethylamino)cyclohexyl]-N-methylbenzamide.

130 (c) **Opium derivatives.** Unless specifically excepted or  
131 unless listed in another schedule, any of the following opium  
132 derivatives, their salts, isomers and salts of isomers, whenever  
133 the existence of these salts, isomers and salts of isomers is  
134 possible within the specific chemical designation:

135 (1) Acetorphine;  
136 (2) Acetyldihydrocodeine;  
137 (3) Benzylmorphine;  
138 (4) Codeine methylbromide;



- 139 (5) Codeine-N-Oxide;
- 140 (6) Cyprenorphine;
- 141 (7) Desomorphine;
- 142 (8) Dihydromorphine;
- 143 (9) Drotebanol;
- 144 (10) Etorphine (except hydrochloride salt);
- 145 (11) Heroin;
- 146 (12) Hydromorphanol;
- 147 (13) Methyldesorphine;
- 148 (14) Methyldihydromorphine;
- 149 (15) Monoacetylmorphine;
- 150 (16) Morphine methylbromide;
- 151 (17) Morphine methylsulfonate;
- 152 (18) Morphine-N-Oxide;
- 153 (19) Myrophine;
- 154 (20) Nicocodeine;
- 155 (21) Nicomorphine;
- 156 (22) Normorphine;
- 157 (23) Pholcodine;
- 158 (24) Thebacon.

159 (d) **Hallucinogenic substances.** Unless specifically excepted  
160 or unless listed in another schedule, any material, compound,  
161 mixture or preparation which contains any quantity of the  
162 following substances, their salts, isomers (whether optical,  
163 positional, or geometric) and salts of isomers, whenever the



164 existence of these salts, isomers and salts of isomers is possible  
165 within the specific chemical designation:

- 166 (1) Alpha-ethyltryptamine;
- 167 (2) 4-bromo-2,5-dimethoxy-amphetamine;
- 168 (3) 4-bromo-2,5-dimethoxyphenethylamine;
- 169 (4) 2,5-dimethoxyamphetamine;
- 170 (5) 2,5-dimethoxy-4-ethylamphetamine (DOET);
- 171 (6) 2,5-dimethoxy-4-(n)-propylthiophenethylamine  
172 (2C-T-7);
- 173 (7) 4-methoxyamphetamine;
- 174 (8) 5-methoxy-3,4-methylenedioxy-amphetamine;
- 175 (9) 4-methyl-2,5-dimethoxy-amphetamine;
- 176 (10) 3,4-methylenedioxy amphetamine;
- 177 (11) 3,4-methylenedioxymethamphetamine (MDMA);
- 178 (12) 3,4-methylenedioxy-N-ethylamphetamine (also known  
179 as N-ethyl-alpha-methyl-3,4(methylenedioxy)phenethylamine, N-ethyl  
180 MDA, MDE, MDEA);
- 181 (13) N-hydroxy-3,4-methylenedioxyamphetamine (also  
182 known as N-hydroxy MDA, N-OHMDA, and  
183 N-hydroxy-alpha-methyl-3,4(methylenedioxy)phenethylamine);
- 184 (14) 3,4,5-trimethoxy amphetamine;
- 185 (15) 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT);
- 186 (16) Alpha-methyltryptamine (also known as AMT);
- 187 (17) Bufotenine;
- 188 (18) Diethyltryptamine;





- 189                   (19) Dimethyltryptamine;
- 190                   (20) 5-methoxy-N,N-diisopropyltryptamine (5-MeO-DIPT);
- 191                   (21) Ibogaine;
- 192                   (22) Lysergic acid diethylamide (LSD);
- 193                   (23) (A) Marijuana (Hemp as defined and regulated
- 194 under Sections 69-25-201 through 69-25-221 and Cannabidiol
- 195 contained in a legend drug product approved by the Federal Food
- 196 and Drug Administration or obtained under Section 41-29-136 are
- 197 exempt under Schedule I);
- 198                               (B) Hashish;
- 199                   (24) Mescaline;
- 200                   (25) Parahexyl;
- 201                   (26) Peyote;
- 202                   (27) N-ethyl-3-piperidyl benzilate;
- 203                   (28) N-methyl-3-piperidyl benzilate;
- 204                   (29) Psilocybin;
- 205                   (30) Psilocyn;
- 206                   (31) Tetrahydrocannabinols, meaning
- 207 tetrahydrocannabinols contained in a plant of the genus Cannabis
- 208 (cannabis plant), as well as the synthetic equivalents of the
- 209 substances contained in the cannabis plant, or in the resinous
- 210 extractives of such plant, and/or synthetic substances,
- 211 derivatives, and their isomers with similar chemical structure and
- 212 pharmacological activity to those substances contained in the
- 213 plant such as the following:



- 214 (A) 1 cis or trans tetrahydrocannabinol;  
215 (B) 6 cis or trans tetrahydrocannabinol;  
216 (C) 3,4 cis or trans tetrahydrocannabinol.

217 (Since nomenclature of these substances is not  
218 internationally standardized, compounds of these structures,  
219 regardless of atomic positions, are covered.)

220 ("Tetrahydrocannabinols" excludes dronabinol and nabilone.)  
221 For purposes of this paragraph, tetrahydrocannabinols do not  
222 include hemp or hemp products regulated under Sections 69-25-201  
223 through 69-25-221.

224 However, the following products are exempted from control:

225 (i) THC-containing industrial products made  
226 from cannabis stalks (e.g., paper, rope and clothing);

227 (ii) Processed cannabis plant materials used  
228 for industrial purposes, such as fiber retted from cannabis stalks  
229 for use in manufacturing textiles or rope;

230 (iii) Animal feed mixtures that contain  
231 sterilized cannabis seeds and other ingredients (not derived from  
232 the cannabis plant) in a formula designed, marketed and  
233 distributed for nonhuman consumption;

234 (iv) Personal care products that contain oil  
235 from sterilized cannabis seeds, such as shampoos, soaps, and body  
236 lotions (if the products do not cause THC to enter the human  
237 body);



238 (v) Hemp as regulated under Sections  
239 69-25-201 through 69-25-221; and  
240 (vi) Any product derived from the hemp plant  
241 designed for human ingestion and/or consumption that is approved  
242 by the United States Food and Drug Administration;

243 (32) Phencyclidine;  
244 (33) Ethylamine analog of phencyclidine (PCE);  
245 (34) Pyrrolidine analog of phencyclidine (PHP, PCPy);  
246 (35) Thiophene analog of phencyclidine;  
247 (36) 1-[1-(2-thienyl)cyclohexyl] pyrrolidine (TCPy);  
248 (37) 4-methylmethcathinone (mephedrone);  
249 (38) 3,4-methylenedioxypropylamphetamine (MDPV);  
250 (39) 2-(2,5-dimethoxy-4-ethylphenyl)ethanamine (2C-E);  
251 (40) 2-(2,5-dimethoxy-4-methylphenyl)ethanamine (2C-D);  
252 (41) 2-(4-chloro-2,5-dimethoxyphenyl)ethanamine (2C-C);  
253 (42) 2-(4-iodo-2,5-dimethoxyphenyl)ethanamine (2C-I);  
254 or 2,5-dimethoxy-4-iodophenethylamine;  
255 (43) 2-[4-(ethylthio)-2,5-dimethoxyphenyl]ethanamine  
256 (2C-T-2);  
257 (44)  
258 2-[4-(isopropylthio)-2,5-dimethoxyphenyl]ethanamine (2C-T-4);  
259 (45) 2-(2,5-dimethoxyphenyl)ethanamine (2C-H);  
260 (46) 2-(2,5-dimethoxy-4-nitro-phenyl)ethanamine (2C-N);  
261 (47) 2-(2,5-dimethoxy-4-(n)-propylphenyl)ethanamine  
262 (2C-P);



263 (48) 3,4-methylenedioxy-N-methylcathinone (methyldone);  
264 (49)  
265 2-(4-bromo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine  
266 (25B-NBOMe; 2C-B-NBOMe; 25B; Cimbi-36);  
267 (50)  
268 2-(4-chloro-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine  
269 (25C-NBOMe; 2C-C-NBOMe; 25C; Cimbi-82);  
270 (51)  
271 2-(4-iodo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine or  
272 N-[(2-methoxyphenyl)methyl]ethanamine (25I-NBOMe; 2C-I-NBOMe; 25I;  
273 Cimbi-5);  
274 (52) 7-bromo-5-(2-chlorophenyl)-1,3-dihydro-2H-1,  
275 4-benzodiazepin-2-one (also known as Phenazepam);  
276 (53) 7-(2-chlorophenyl)-4-ethyl-13-methyl-3-thia-1,8,  
277 11,12-tetraazatricyclo[8.3.0.0]trideca-2(6),4,7,10,12-pentaene  
278 (also known as Etizolam);  
279 (54) Salvia divinorum;  
280 (55) Synthetic cannabinoids. Unless specifically  
281 excepted or unless listed in another schedule, any material,  
282 compound, mixture, or preparation which contains any quantity of a  
283 synthetic cannabinoid found in any of the following chemical  
284 groups, whether or not substituted to any extent, or any of those  
285 groups which contain any synthetic cannabinoid salts, isomers, or  
286 salts of isomers, whenever the existence of such salts, isomers,  
287 or salts of isomers is possible within the specific chemical



288 designation, including all synthetic cannabinoid chemical  
289 analogues in such groups:

290 (A) (6aR,10aR)-9-(hydroxymethyl)-6,  
291 6-dimethyl-3-(2-methyloctan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c]  
292 chromen-1-ol (also known as HU-210 or  
293 1,1-dimethylheptyl-11-hydroxy-delta8-tetrahydrocannabinol);

294 (B) Naphthoylindoles and naphthylmethylindoles,  
295 being any compound structurally derived from 3-(1-naphthoyl)indole  
296 or 1H-indol-3-yl-(1-naphthyl)methane, whether or not substituted  
297 in the indole ring to any extent, or in the naphthyl ring to any  
298 extent;

299 (C) Naphthoylpyrroles, being any compound  
300 structurally derived from 3-(1-naphthoyl)pyrrole, whether or not  
301 substituted in the pyrrole ring to any extent, or in the naphthyl  
302 ring to any extent;

303 (D) Naphthylmethylindenes, being any compound  
304 structurally derived from 1-(1-naphthylmethyl)indene, whether or  
305 not substituted in the indene ring to any extent or in the  
306 naphthyl ring to any extent;

307 (E) Phenylacetylindoles, being any compound  
308 structurally derived from 3-phenylacetylindole, whether or not  
309 substituted in the indole ring to any extent or in the phenyl ring  
310 to any extent;

311 (F) Cyclohexylphenols, being any compound  
312 structurally derived from 2-(3-hydroxycyclohexyl)phenol, whether



313 or not substituted in the cyclohexyl ring to any extent or in the  
314 phenolic ring to any extent;

315 (G) Benzoylindoles, whether or not substituted in  
316 the indole ring to any extent or in the phenyl ring to any extent;

317 (H) Adamantoylindoles, whether or not substituted  
318 in the indole ring to any extent or in the adamantoyl ring system  
319 to any extent;

320 (I) Tetrahydro derivatives of cannabinal and  
321 3-alkyl homologues of cannabinal or of its tetrahydro derivatives,  
322 except where contained in cannabis or cannabis resin;

323 (J) 3-Cyclopropylmethanone indole or  
324 3-Cyclobutylmethanone indole or 3-Cyclopentylmethanone indole by  
325 substitution at the nitrogen atom of the indole ring, whether or  
326 not further substituted in the indole ring to any extent, whether  
327 or not substituted on the cyclopropyl, cyclobutyl or cyclopentyl  
328 rings to any extent;

329 (K) Quinoliny ester indoles, being any compound  
330 structurally derived from 1H-indole-3carboxylic acid-8-quinoliny  
331 ester, whether or not substituted in the indole ring to any extent  
332 or the quinolone ring to any extent;

333 (L) 3-carboxamide-1H-indazoles, whether or not  
334 substituted in the indazole ring to any extent and substituted to  
335 any degree on the carboxamide nitrogen and  
336 3-carboxamide-1H-indoles, whether or not substituted in the indole



337 ring to any extent and substituted to any degree on the  
338 carboxamide nitrogen;

339 (M) Cycloalkanemethanone Indoles, whether or not  
340 substituted at the nitrogen atom on the indole ring, whether or  
341 not further substituted in the indole ring to any extent, whether  
342 or not substituted on the cycloalkane ring to any extent.

343 (e) **Depressants.** Unless specifically excepted or unless  
344 listed in another schedule, any material, compound, mixture, or  
345 preparation which contains any quantity of the following  
346 substances having a depressant effect on the central nervous  
347 system, including their salts, isomers, and salts of isomers,  
348 whenever the existence of such salts, isomers, and salts of  
349 isomers is possible within the specific chemical designation:

350 (1) Clonazolam,  
351 6-(2-chlorophenyl)-1-methyl-8-nitro-4H-[1,2,4]triazolo[4,3-a][1,4]  
352 benzodiazepine;

353 (2) Flualprazolam,  
354 8-chloro-6-(2-fluorophenyl)-1-methyl-4H-[1,2,4]triazolo[4,3-a][1,4  
355 ]benzodiazepine;

356 (3) Flubromazepam,  
357 7-bromo-5-(2-fluorophenyl)-1,3-dihydro-2H-1,4-benzodiazepin-2-one;

358 (4) Flubromazolam,  
359 8-bromo-6-(2-fluorophenyl)-1-methyl-4H-[1,2,4]triazolo[4,3-a][1,4]  
360 benzodiazepin;



361 (5) Gamma-hydroxybutyric acid (other names include:  
362 GHB, gamma-hydroxybutyrate; 4-hydroxybutyrate; 4-hydroxybutanoic  
363 acid; sodium oxybate; sodium oxybutyrate);

364 (6) Mecloqualone;

365 (7) Methaqualone.

366 (f) **Stimulants.** Any material, compound, mixture or  
367 preparation which contains any quantity of the following central  
368 nervous system stimulants including optical salts, isomers and  
369 salts of isomers unless specifically excepted or unless listed in  
370 another schedule:

371 (1) Aminorex;

372 (2) N-benzylpiperazine (also known as BZP and  
373 1-benzylpiperazine);

374 (3) Cathinone;

375 (4) Fenethylamine;

376 (5) Methcathinone;

377 (6) 4-methylaminorex (also known as  
378 2-amino-4-methyl-5-phenyl-2-oxazoline);

379 (7) N-ethylamphetamine;

380 (8) Any material, compound, mixture or preparation  
381 which contains any quantity of N,N-dimethylamphetamine. (Other  
382 names include: N,N,-alpha-trimethyl-benzeneethanamine and  
383 N,N-alpha-trimethylphenethylamine);

384 (9) **Synthetic cathinones.** (A) Unless listed in  
385 another schedule, any compound other than bupropion that is





386 structurally derived from 2-Amino-1-phenyl-1-propanone by  
387 modification in any of the following ways:

388 (i) By substitution in the phenyl ring to any  
389 extent with alkyl, alkoxy, alkylendioxy, haloalkyl or halide  
390 substituents, whether or not further substituted in the phenyl  
391 ring by one or more other univalent substituents;

392 (ii) By substitution at the 3-position with  
393 an alkyl substituent;

394 (iii) By substitution at the nitrogen atom  
395 with alkyl or dialkyl groups, or by inclusion of the nitrogen atom  
396 in a cyclic structure.

397 (B) The compounds covered in this paragraph (9)  
398 include, but are not limited to, any material, compound, mixture  
399 or preparation which contains any quantity of a synthetic  
400 cathinone found in any of the following compounds, whether or not  
401 substituted to any extent, or any of these compounds which contain  
402 any synthetic cathinone, or salts, isomers, or salts of isomers,  
403 whenever the existence of such salts, isomers or salts of isomers  
404 is possible, unless specifically excepted or listed in another  
405 schedule:

406 (i) 4-methyl-N-ethylcathinone ("4-MEC");

407 (ii) 4-methyl-alpha-pyrrolidinopropiophenone  
408 ("4-MePPP");

409 (iii) Alpha-pyrrolidinopentiophenone  
410 ("α-PVP");



411 (iv)  
412 1-(1,3-benzodioxol-5-yl)-2-(methylamino)butan-1-one ("butylone");  
413 (v) 2-(methylamino)-1-phenylpentan-1-one  
414 ("pentedrone");  
415 (vi)  
416 1-(1,3-benzodioxol-5-yl)-2-(methylamino)pentan-1-one  
417 ("pentylone");  
418 (vii) 4-fluoro-N-methylcathinone ("4-FMC");  
419 (viii) 3-fluoro-N-methylcathinone ("3-FMC");  
420 (ix)  
421 1-(naphthalen-2-yl)-2-(pyrrolidin-1-yl)pentan-1-one ("naphyrone");  
422 (x) Alpha-pyrrolidinobutiophenone ("α-PBP");  
423 and  
424 (xi)  
425 1-(1,3-benzodioxol-5-yl)-2-(ethylamino)-pentan-1-one  
426 (N-ethylpentylone, ephylone).  
427 (10) (A) Mitragynine; and  
428 (B) 7-hydroxymitragynine.

429 **SECTION 2.** This act shall take effect and be in force from  
430 and after July 1, 2022.

